Update on Rifampin and Rifabutin Drug Interactions

Baciewicz, Anne M.; Chrisman, Cary R.; Finch, Christopher K.; Self, Timothy H.

doi:10.1097/maj.0b013e31814a586a

Cited by 129 publications

(96 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The cytochrome P450 (CYP) enzyme system in the liver plays a significant role in drug metabolism, and drugs (possibly including the herbal medication, St John's Wort) that induce these enzymes can cause increased elimination of contraceptive steroids, resulting in reduced reliability and, consequently, unplanned pregnancy. 3 A variety of potent enzyme inducers known to have deleterious effects on hormonal contraceptives include some antiepileptics (carbamazepine, oxcarbazepine, phenytoin, phenobarbital, primidone, topiramate), [16][17][18][19] antibiotics (rifampicin, rifabutin), [20][21][22][23][24] antifungals (griseofulvin), 25 protease inhibitors (amprenavir, atazanavir, nelfinavir, lopinavir, saquinavir, ritonavir), 26 and non-nucleoside reverse transcriptase inhibitors (efavirenz, nevirapine). 27 There have been sporadic reports of Implanon failure due to suspected interaction with concomitantly administered drugs, resulting in intrauterine 10,11,28 or ectopic [29][30][31] pregnancies.…”

Section: Discussionmentioning

confidence: 99%

Failure of Implanon® on antituberculous therapy

Gbolade¹

2010

OAJC

View full text Add to dashboard Cite

Implanon ® , a contraceptive implant, is increasingly being used because of its efficacy and nonuser-dependent nature. However, as for other steroid contraceptives, its efficacy can be reduced by enzyme-inducing drugs, such as antituberculous medication, resulting in unplanned pregnancy. We present the case of a 27-year-old para 1 + 0 referred to us for termination of a pregnancy that resulted from failure of Implanon during concomitant treatment with Rifinah ® (a rifampicin-isoniazid combination). All health care providers should be aware of the adverse effects of hepatic enzyme inducers on hormonal contraceptives, obtain details of current contraceptive methods from women of reproductive age, and refer them to contraceptive and reproductive health care professionals as appropriate for optimal management. This will ensure that such women do not experience the psychologic trauma of a termination of pregnancy.

show abstract

Section: Discussionmentioning

confidence: 99%

Failure of Implanon® on antituberculous therapy

Gbolade¹

2010

OAJC

View full text Add to dashboard Cite

show abstract

“…Rifampin is a potent inducer of the cytochrome P450 (CYP) oxidative pathway, in particular the CYP3A4 enzymes in both the liver and intestinal wall as well as the P glycoprotein (PGP) transport system in the intestine (14,274). This induction can result in significant interactions with many drugs including antimicrobial agents (14,199).…”

Section: Drug Interactionsmentioning

confidence: 99%

Rifampin Combination Therapy for Nonmycobacterial Infections

2010

View full text Add to dashboard Cite

SUMMARY The increasing emergence of antimicrobial-resistant organisms, especially methicillin-resistant Staphylococcus aureus (MRSA), has resulted in the increased use of rifampin combination therapy. The data supporting rifampin combination therapy in nonmycobacterial infections are limited by a lack of significantly controlled clinical studies. Therefore, its current use is based upon in vitro or in vivo data or retrospective case series, all with major limitations. A prominent observation from this review is that rifampin combination therapy appears to have improved treatment outcomes in cases in which there is a low organism burden, such as biofilm infections, but is less effective when effective surgery to obtain source control is not performed. The clinical data support rifampin combination therapy for the treatment of prosthetic joint infections due to methicillin-sensitive S. aureus (MSSA) after extensive debridement and for the treatment of prosthetic heart valve infections due to coagulase-negative staphylococci. Importantly, rifampin-vancomycin combination therapy has not shown any benefit over vancomycin monotherapy against MRSA infections either clinically or experimentally. Rifampin combination therapy with daptomycin, fusidic acid, and linezolid needs further exploration for these severe MRSA infections. Lastly, an assessment of the risk-benefits is needed before the addition of rifampin to other antimicrobials is considered to avoid drug interactions or other drug toxicities.

show abstract

“…(43,44) The possibility of interaction between rifampin and other drugs calls for a thorough history taking that focuses on the drugs currently used by patients. There is a decrease in the plasma concentrations of the following drugs when administered concomitantly with rifampin: oral hypoglycemic agents, the doses of which might have to be increased, and which might sometimes have to be replaced with insulin (45) ; protease inhibitors and non-nucleoside reverse transcriptase inhibitors, although efavirenz or a combination of saquinavir and ritonavir can be used without the need for discontinuing rifampin (46) ; oral anticoagulants, the doses of which should be carefully monitored, as should their international normalized ratios; and other drugs, such as valproic acid, antidepressants (nortriptyline and sertraline), barbiturates, benzodiazepines, beta-adrenergic blocking agents, ketoconazole, chloramphenicol, contraceptives, corticosteroids, cyclosporine, dapsone, digoxin, diltiazem, enalapril, phenytoin, fluconazole, haloperidol, itraconazole, macrolides, nifedipine, quinidine, rapamycin, simvastatin, theophylline, and verapamil.…”

Section: Central Nervous Systemmentioning

confidence: 99%

Drogas antituberculose: interações medicamentosas, efeitos adversos e utilização em situações especiais - parte 1: fármacos de primeira linha

et al. 2010

View full text Add to dashboard Cite

The main objectives of tuberculosis therapy are to cure the patients and to minimize the possibility of transmission of the bacillus to healthy subjects. Adverse effects of antituberculosis drugs or drug interactions (among antituberculosis drugs or between antituberculosis drugs and other drugs) can make it necessary to modify or discontinue treatment. We briefly review the new guidelines for the pharmacological treatment of tuberculosis, introduced by the Brazilian National Ministry of Health in 2009, and describe the general mechanism of action, absorption, metabolization, and excretion of the first-line drugs used in the basic regimen. We describe adverse drug reactions and interactions (with other drugs, food, and antacids), as well as the most appropriate approach to special situations, such as pregnancy, breastfeeding, liver failure, and kidney failure. We also describe the mechanisms by which the interactions among the antituberculosis drugs used in the basic regimen can cause druginduced hepatitis, and we discuss the alternatives in this situation.Keywords: Tuberculosis; Drug interactions; Antibiotics, antitubercular; Pharmacologic actions; Drug toxicity; Drug-induced liver injury. ResumoOs objetivos principais do tratamento da tuberculose são curar o paciente e minimizar a possibilidade de transmissão do bacilo para indivíduos saudáveis. Reações adversas ou interações das drogas antituberculose entre si e com outros fármacos podem causar modificação ou descontinuação da terapêutica. Revisamos sucintamente o novo tratamento farmacológico da tuberculose introduzido pelo Ministério da Saúde do Brasil em 2009 e mostramos os mecanismos gerais de ação, absorção, metabolização e excreção dos medicamentos utilizados no esquema básico. Descrevemos as reações adversas e as interações (com medicamentos, alimentos e antiácidos) assim como a abordagem mais adequada para situações especiais, como gravidez, amamentação, insuficiência hepática e renal. Também descrevemos os mecanismos pelos quais as interações das drogas antituberculose do esquema básico podem causar hepatite medicamentosa e as possíveis alternativas nessa situação.Descritores: Tuberculose; Interações de medicamentos; Antibióticos antituberculose; Ações farmacológicas; Toxicidade de drogas; Doença hepática induzida por drogas.

show abstract

Update on Rifampin and Rifabutin Drug Interactions

Cited by 129 publications

References 63 publications

Failure of Implanon® on antituberculous therapy

Failure of Implanon® on antituberculous therapy

Rifampin Combination Therapy for Nonmycobacterial Infections

Drogas antituberculose: interações medicamentosas, efeitos adversos e utilização em situações especiais - parte 1: fármacos de primeira linha

Contact Info

Product

Resources

About

Update on Rifampin and Rifabutin Drug Interactions

Cited by 129 publications

References 63 publications

Failure of Implanon&reg; on antituberculous therapy

Failure of Implanon&reg; on antituberculous therapy

Rifampin Combination Therapy for Nonmycobacterial Infections

Drogas antituberculose: interações medicamentosas, efeitos adversos e utilização em situações especiais - parte 1: fármacos de primeira linha

Contact Info

Product

Resources

About

Failure of Implanon® on antituberculous therapy

Failure of Implanon® on antituberculous therapy